NCT05970263 - IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US | Biotech Hunter

Timeline

Start Date

January 19, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

COPD

Interventions

DRUG

Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.

2 inhalations twice daily administered by oral inhalation, from a metered dose inhaler, over a 12-month follow-up period.

OTHER

External Comparator

Received any inhaled therapy, excluding triple inhaled maintenance therapy, during index hospitalization and refilled within 30 days before or after discharge from index hospitalization